title: Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
authors.affiliation: University of South Carolina and the Hollings Cancer Center of the Medical University of South Carolina, Columbia and Charleston, SC 29208, USA. Electronic address: bennettc@sccp.sc.edu.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
authors.affiliation: Tulane University School of Medicine, New Orleans, LA, USA.
authors.forename: Oliver A
authors.initials: OA
authors.lastname: Sartor
authors.affiliation: University of Nebraska Medical Center, Omaha, NE, USA.
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
authors.affiliation: MD Anderson Cancer Center and the University of Texas, Houston, TX, USA.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000191:economics* / Q000627:therapeutic use*; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use*; D004465:Economic Competition; D005102:Health Expenditures; D006301:Health Services Needs and Demand / Q000191:economics; D006801:Humans; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic